

# Thomas S Stroup

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3890970/publications.pdf>

Version: 2024-02-01

198  
papers

42,877  
citations

10389

72  
h-index

4117

175  
g-index

203  
all docs

203  
docs citations

203  
times ranked

36785  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biological insights from 108 schizophrenia-associated genetic loci. <i>Nature</i> , 2014, 511, 421-427.	27.8	6,934
2	Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. <i>New England Journal of Medicine</i> , 2005, 353, 1209-1223.	27.0	5,335
3	LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. <i>Nature Genetics</i> , 2015, 47, 291-295.	21.4	3,905
4	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. <i>Nature Genetics</i> , 2013, 45, 984-994.	21.4	2,067
5	Genome-wide association study identifies five new schizophrenia loci. <i>Nature Genetics</i> , 2011, 43, 969-976.	21.4	1,758
6	Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. <i>American Journal of Human Genetics</i> , 2015, 97, 576-592.	6.2	1,098
7	Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2006, 355, 1525-1538.	27.0	1,067
8	Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. <i>Schizophrenia Research</i> , 2005, 80, 19-32.	2.0	1,016
9	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	27.8	929
10	Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007, 64, 633.	12.3	928
11	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> , 2017, 49, 27-35.	21.4	838
12	Premature Mortality Among Adults With Schizophrenia in the United States. <i>JAMA Psychiatry</i> , 2015, 72, 1172.	11.0	770
13	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006, 163, 600-610.	7.2	760
14	Physical Health Monitoring of Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2004, 161, 1334-1349.	7.2	732
15	A National Study of Violent Behavior in Persons With Schizophrenia. <i>Archives of General Psychiatry</i> , 2006, 63, 490.	12.3	648
16	Microduplications of 16p11.2 are associated with schizophrenia. <i>Nature Genetics</i> , 2009, 41, 1223-1227.	21.4	646
17	Partitioning Heritability of Regulatory and Cell-Type-Specific Variants across 11 Common Diseases. <i>American Journal of Human Genetics</i> , 2014, 95, 535-552.	6.2	569
18	The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development. <i>Schizophrenia Bulletin</i> , 2003, 29, 15-31.	4.3	549

#	ARTICLE	IF	CITATIONS
19	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006, 163, 600.	7.2	513
20	Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. <i>Schizophrenia Research</i> , 2006, 86, 15-22.	2.0	473
21	A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. <i>Schizophrenia Research</i> , 2005, 80, 45-53.	2.0	466
22	Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial. <i>Neuropsychopharmacology</i> , 2006, 31, 2033-2046.	5.4	408
23	Barriers to Employment for People With Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 411-417.	7.2	390
24	Genomewide association for schizophrenia in the CATIE study: results of stage 1. <i>Molecular Psychiatry</i> , 2008, 13, 570-584.	7.9	332
25	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006, 163, 611-622.	7.2	312
26	Management of common adverse effects of antipsychotic medications. <i>World Psychiatry</i> , 2018, 17, 341-356.	10.4	294
27	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. <i>Schizophrenia Research</i> , 2008, 101, 273-286.	2.0	258
28	Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 2080-2089.	7.2	247
29	Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 428-436.	7.2	246
30	Does switching to a new antipsychotic improve outcomes?. <i>Schizophrenia Research</i> , 2009, 107, 22-29.	2.0	232
31	Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD. <i>American Journal of Psychiatry</i> , 2011, 168, 831-839.	7.2	232
32	The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1751-1762.	2.2	230
33	Extrapyramidal side-effects of antipsychotics in a randomised trial. <i>British Journal of Psychiatry</i> , 2008, 193, 279-288.	2.8	228
34	Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 336-346.	4.3	228
35	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006, 163, 611.	7.2	221
36	Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. <i>Schizophrenia Research</i> , 2008, 105, 175-187.	2.0	195

#	ARTICLE	IF	CITATIONS
37	The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. <i>Schizophrenia Research</i> , 2005, 80, 9-18.	2.0	189
38	Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. <i>American Journal of Psychiatry</i> , 2008, 165, 978-987.	7.2	182
39	Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2008, 193, 37-43.	2.8	171
40	The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 500-508.	2.2	165
41	A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). <i>American Journal of Psychiatry</i> , 2011, 168, 947-956.	7.2	158
42	Effectiveness of Switching Antipsychotic Medications. <i>American Journal of Psychiatry</i> , 2006, 163, 2090-2095.	7.2	153
43	Effectiveness of Switching From Antipsychotic Polypharmacy to Monotherapy. <i>American Journal of Psychiatry</i> , 2011, 168, 702-708.	7.2	149
44	Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005, 80, 33-43.	2.0	146
45	Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. <i>Molecular Psychiatry</i> , 2011, 16, 76-85.	7.9	141
46	Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. <i>Molecular Psychiatry</i> , 2011, 16, 321-332.	7.9	141
47	Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 415-427.	7.2	138
48	Substance Use in Persons With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2006, 194, 164-172.	1.0	137
49	Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. <i>American Journal of Psychiatry</i> , 2016, 173, 166-173.	7.2	134
50	Results of phase 3 of the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2009, 107, 1-12.	2.0	129
51	Effectiveness of Paliperidone Palmitate vs Haloperidol Decanoate for Maintenance Treatment of Schizophrenia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1978.	7.4	129
52	Causes of schizophrenia reported by patients' family members in China. <i>British Journal of Psychiatry</i> , 2000, 177, 20-25.	2.8	123
53	Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects. <i>Biological Psychiatry</i> , 2010, 67, 279-282.	1.3	122
54	Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. <i>American Journal of Human Genetics</i> , 2018, 102, 1185-1194.	6.2	119

#	ARTICLE	IF	CITATIONS
55	Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2013, 170, 1032-1040.	7.2	118
56	Determining when impairment constitutes incapacity for informed consent in schizophrenia research. <i>British Journal of Psychiatry</i> , 2007, 191, 38-43.	2.8	114
57	Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial. <i>Psychiatric Services</i> , 2008, 59, 500-506.	2.0	110
58	Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. <i>Schizophrenia Bulletin</i> , 2013, 39, 564-574.	4.3	109
59	Informing sequential clinical decision-making through reinforcement learning: an empirical study. <i>Machine Learning</i> , 2011, 84, 109-136.	5.4	105
60	Geographic and Clinical Variation in Clozapine Use in the United States. <i>Psychiatric Services</i> , 2014, 65, 186-192.	2.0	104
61	Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia. <i>Neuropsychopharmacology</i> , 2011, 36, 616-626.	5.4	103
62	Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. <i>Schizophrenia Bulletin</i> , 2003, 29, 33-43.	4.3	102
63	Sexually dimorphic aging of dendritic morphology in CA1 of hippocampus. <i>Hippocampus</i> , 2005, 15, 97-103.	1.9	97
64	Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. <i>Biological Psychiatry</i> , 2009, 66, 1013-1022.	1.3	91
65	Feasibility and Pilot Efficacy Results From the Multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1016-1022.	2.2	85
66	The NIMH-CATIE Schizophrenia Study: What Did We Learn?. <i>American Journal of Psychiatry</i> , 2011, 168, 770-775.	7.2	84
67	Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005, 80, 1-8.	2.0	80
68	NCAM1 and Neurocognition in Schizophrenia. <i>Biological Psychiatry</i> , 2007, 61, 902-910.	1.3	80
69	Genome-wide association study of antipsychotic-induced QTc interval prolongation. <i>Pharmacogenomics Journal</i> , 2012, 12, 165-172.	2.0	78
70	Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). <i>Journal of Clinical Psychiatry</i> , 2012, 73, 526-532.	2.2	78
71	Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer's Disease Patients: The CATIE-AD Study. <i>American Journal of Psychiatry</i> , 2009, 166, 583-590.	7.2	76
72	Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 1057-1065.	4.3	76

#	ARTICLE	IF	CITATIONS
73	Measuring outcome priorities and preferences in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2005, 187, 529-536.	2.8	74
74	The association between weight change and symptom reduction in the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2011, 128, 166-170.	2.0	73
75	Deaths of people with mental illness during interactions with law enforcement. <i>International Journal of Law and Psychiatry</i> , 2018, 58, 110-116.	0.9	72
76	Assessment of Medicaid Managed Behavioral Health Care for Persons With Serious Mental Illness. <i>Psychiatric Services</i> , 2005, 56, 1245-1253.	2.0	70
77	Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 2080.	7.2	65
78	Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i>Schizophrenia Research</i> , 2008, 103, 104-109.	2.0	64
79	Generating comparative evidence on new drugs and devices before approval. <i>Lancet</i> , The, 2020, 395, 986-997.	13.7	59
80	Substance Use and Psychosocial Functioning in Schizophrenia Among New Enrollees in the NIMH CATIE Study. <i>Psychiatric Services</i> , 2006, 57, 1110-1116.	2.0	57
81	Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia. <i>Biological Psychiatry</i> , 2008, 63, 32-41.	1.3	57
82	Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 295-303.	2.2	57
83	Substance use and schizophrenia: Adverse correlates in the CATIE study sample. <i>Schizophrenia Research</i> , 2011, 132, 177-182.	2.0	56
84	Age-Specific Prevalence and Incidence of Dementia Diagnoses Among Older US Adults With Schizophrenia. <i>JAMA Psychiatry</i> , 2021, 78, 632.	11.0	56
85	The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. <i>Schizophrenia Research</i> , 2008, 100, 39-52.	2.0	53
86	Polypharmacy for schizophrenia. <i>Current Opinion in Psychiatry</i> , 2013, 26, 208-213.	6.3	53
87	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. <i>International Journal of Epidemiology</i> , 2015, 44, 1706-1721.	1.9	53
88	Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 133-146.	46.4	52
89	Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 428.	7.2	52
90	Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 669-675.	2.2	46

#	ARTICLE	IF	CITATIONS
91	Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. <i>International Journal of Clinical Practice</i> , 2006, 60, 933-940.	1.7	43
92	Paliperidone Palmitate for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 1124-1127.	4.3	40
93	Schizophrenia genetic variants are not associated with intelligence. <i>Psychological Medicine</i> , 2013, 43, 2563-2570.	4.5	40
94	Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits. <i>Current Behavioral Neuroscience Reports</i> , 2016, 3, 165-175.	1.3	40
95	Effectiveness of Switching Antipsychotic Medications. <i>American Journal of Psychiatry</i> , 2006, 163, 2090.	7.2	39
96	A multiple imputation strategy for sequential multiple assignment randomized trials. <i>Statistics in Medicine</i> , 2014, 33, 4202-4214.	1.6	38
97	Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 508.	11.0	38
98	Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 415.	7.2	38
99	Heterogeneity of Treatment Effects in Schizophrenia. <i>American Journal of Medicine</i> , 2007, 120, S26-S31.	1.5	35
100	The impact of obesity on health care costs among persons with schizophrenia. <i>General Hospital Psychiatry</i> , 2009, 31, 1-7.	2.4	34
101	An Initiative to Improve Clozapine Prescribing in New York State. <i>Psychiatric Services</i> , 2016, 67, 369-371.	2.0	34
102	Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span. <i>JAMA Psychiatry</i> , 2021, 78, 876.	11.0	34
103	Aripiprazole Versus Haloperidol in Combination With Clozapine for Treatment-Resistant Schizophrenia in Routine Clinical Care. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 266-273.	1.4	33
104	Clozapine for Schizophrenia: State Variation in Evidence-Based Practice. <i>Psychiatric Services</i> , 2016, 67, 152-152.	2.0	33
105	Integrated Care: Tobacco Use and Mental Illness: A Wake-Up Call for Psychiatrists. <i>Psychiatric Services</i> , 2014, 65, 1406-1408.	2.0	31
106	Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial. <i>Schizophrenia Research</i> , 2013, 146, 190-195.	2.0	30
107	Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 75-80.	2.2	29
108	A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 336-340.	1.7	28



#	ARTICLE	IF	CITATIONS
109	Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study. <i>Schizophrenia Research</i> , 2011, 130, 47-52.	2.0	28
110	Science and Recovery in Schizophrenia. <i>Psychiatric Services</i> , 2008, 59, 487-496.	2.0	28
111	What CATIE Found: Results From the Schizophrenia Trial. <i>Psychiatric Services</i> , 2008, 59, 500-506.	2.0	28
112	Factors Associated With Initiation on Clozapine and on Other Antipsychotics Among Medicaid Enrollees. <i>Psychiatric Services</i> , 2012, 63, 1146-1149.	2.0	26
113	An international survey examining the impact of the COVID-19 pandemic on telehealth use among mental health professionals. <i>Journal of Psychiatric Research</i> , 2022, 148, 188-196.	3.1	26
114	Drugs of the Psychopharmacological Revolution in Clinical Psychiatry. <i>Psychiatric Services</i> , 2000, 51, 1254-1258.	2.0	25
115	The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 1298-1300.	1.7	25
116	Effectiveness of long-acting injectable antipsychotics: a clinical perspective: Table A1. <i>Evidence-Based Mental Health</i> , 2015, 18, 36-39.	4.5	25
117	Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 103-111.	1.4	24
118	The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. <i>British Journal of Psychiatry</i> , 2006, 189, 391-392.	2.8	23
119	Oral paliperidone for schizophrenia. <i>The Cochrane Library</i> , 2008, , CD006369.	2.8	22
120	Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: a descriptive study. <i>Journal of Community Psychology</i> , 2011, 39, 76-88.	1.8	22
121	Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. <i>Schizophrenia Research</i> , 2019, 208, 182-189.	2.0	22
122	Management of Medical Illness in Persons With Schizophrenia. <i>Psychiatric Annals</i> , 2000, 30, 35-40.	0.1	22
123	Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1587-1591.	2.0	21
124	Paliperidone for Treatment of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 34, 419-422.	4.3	20
125	Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia. <i>Journal of Behavioral Health Services and Research</i> , 2008, 35, 215-225.	1.4	19
126	Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). <i>Frontiers in Genetics</i> , 2011, 2, 56.	2.3	19



#	ARTICLE	IF	CITATIONS
127	Electronic Health Records in Mental Health Research: A Framework for Developing Valid Research Methods. <i>Psychiatric Services</i> , 2015, 66, 193-196.	2.0	19
128	Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs. <i>American Journal of Veterinary Research</i> , 2006, 67, 1173-1178.	0.6	18
129	Service Use and Health Status of Persons With Severe Mental Illness in Full-Risk and No-Risk Medicaid Programs. <i>Psychiatric Services</i> , 2002, 53, 293-298.	2.0	17
130	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>Focus (American Tj ETQq0 0 0 rgBT Overlock 10 Tf 50 6</i>	0.0	17
131	Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. <i>Statistics in Biopharmaceutical Research</i> , 2011, 3, 253-265.	0.8	16
132	Mortality risk of antipsychotic augmentation for adult depression. <i>PLoS ONE</i> , 2020, 15, e0239206.	2.5	16
133	Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States. <i>Psychiatric Services</i> , 2022, 73, 492-500.	2.0	15
134	Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2016, 67, 1124-1130.	2.0	13
135	Antipsychotic Medication Treatment Patterns in Adult Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 55-61.	2.2	13
136	Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals. <i>Schizophrenia Bulletin</i> , 2007, 34, 266-274.	4.3	12
137	AKT1 and Neurocognition in Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 169-177.	2.3	12
138	Evaluation of "Subject Advocate" Procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. <i>Schizophrenia Bulletin</i> , 2005, 32, 147-152.	4.3	11
139	What Can Large Simple Trials Do for Psychiatry?. <i>American Journal of Psychiatry</i> , 2011, 168, 117-119.	7.2	11
140	Pragmatic design in randomized controlled trials. <i>Psychological Medicine</i> , 2015, 45, 225-230.	4.5	11
141	Substance Use and Psychosocial Functioning in Schizophrenia Among New Enrollees in the NIMH CATIE Study. <i>Psychiatric Services</i> , 2006, 57, 1110-1116.	2.0	11
142	Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2009, 113, 12-18.	2.0	10
143	Criminal Justice System Involvement Among People with Schizophrenia. <i>Community Mental Health Journal</i> , 2011, 47, 727-736.	2.0	10
144	Risperidone Versus Olanzapine for Treatment of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2006, 33, 1274-1276.	4.3	9

#	ARTICLE	IF	CITATIONS
145	No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1115-1117.	1.7	9
146	Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia. Journal of Psychiatry and Brain Science, 2019, 4, .	0.5	9
147	Guest Editors' Introduction: What Can Large Pragmatic Clinical Trials Do for Public Mental Health Care?. Schizophrenia Bulletin, 2003, 29, 1-6.	4.3	8
148	Medications for First-Episode Psychosis: Making a Good Start. American Journal of Psychiatry, 2015, 172, 209-211.	7.2	8
149	Correlates of family burden under medicaid managed mental health care. Administration and Policy in Mental Health and Mental Health Services Research, 2001, 29, 117-128.	2.1	7
150	Schizophrenia, VI: Treatments. American Journal of Psychiatry, 2003, 160, 1748-1748.	7.2	7
151	Dr. Rosenheck and Colleagues Reply. American Journal of Psychiatry, 2007, 164, 678-680.	7.2	7
152	Violence risk assessment for young adults receiving treatment for early psychosis. International Journal of Law and Psychiatry, 2021, 76, 101701.	0.9	6
153	Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH Schizophrenia Trials Network Study. Clinical Schizophrenia and Related Psychoses, 2007, 1, 69-72.	1.4	6
154	Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome. , 0, , 189-206.		4
155	Population pharmacokinetics of antipsychotics. , 2010, , 267-280.		4
156	Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United States. Psychiatric Services, 2018, 69, 605-608.	2.0	4
157	What Is the Role of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia?. Journal of Clinical Psychiatry, 2014, 75, 1261-1262.	2.2	4
158	Feasibility and Utility of Different Approaches to Violence Risk Assessment for Young Adults Receiving Treatment for Early Psychosis. Community Mental Health Journal, 2022, 58, 1130-1140.	2.0	4
159	Suicide Reduction in Schizophrenia via Exercise (SUnRISE): study protocol for a multi-site, single-blind, randomized clinical trial of aerobic exercise for suicide risk reduction in individuals with schizophrenia. Trials, 2020, 21, 871.	1.6	3
160	Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications. Journal of Clinical Psychiatry, 2018, 80, .	2.2	3
161	Schizophrenia, Drug Therapy, and Monitoring. New England Journal of Medicine, 2004, 350, 415-416.	27.0	2
162	Revised PORT Recommendations. Schizophrenia Bulletin, 2004, 30, 609-611.	4.3	2

#	ARTICLE	IF	CITATIONS
163	Dr. Lieberman and Colleagues Reply. American Journal of Psychiatry, 2006, 163, 555-a-556.	7.2	2
164	Vasodilators in Aortic Regurgitation. New England Journal of Medicine, 2006, 354, 300-303.	27.0	2
165	Review: higher rates of attrition in antipsychotic treatment arms of placebo controlled trials than in trials with active comparators. Evidence-Based Mental Health, 2006, 9, 70-70.	4.5	2
166	Drs. Stroup, Rosenheck, Essock, and Lieberman Reply. American Journal of Psychiatry, 2007, 164, 1266-1267.	7.2	2
167	Neurocognition. , 0, , 97-119.		2
168	La necesidad de determinar la mejor alternativa para personas con esquizofrenia que no responden al tratamiento. Revista De Psiquiatría Y Salud Mental, 2013, 6, 1-3.	1.8	2
169	The enduring challenge of antipsychotic non-adherence. World Psychiatry, 2013, 12, 236-237.	10.4	2
170	Drug information update: paliperidone palmitate for schizophrenia. The Psychiatrist, 2013, 37, 164-166.	0.3	2
171	A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. Schizophrenia Research, 2020, 220, 92-97.	2.0	2
172	Clinical and Community-Service Activities of Psychiatric Teaching Hospitals. Academic Psychiatry, 1999, 23, 123-127.	0.9	1
173	Study design and protocol development process. , 2010, , 1-21.		1
174	Violence in schizophrenia: prevalence, correlates, and treatment effectiveness. , 0, , 207-236.		1
175	Extrapyramidal side effects. , 2010, , 156-172.		1
176	Response to Baandrup Letter. American Journal of Psychiatry, 2011, 168, 1117-1117.	7.2	1
177	The NIMH-CATIE Schizophrenia Study: What Did We Learn?. Focus (American Psychiatric Publishing), 2012, 10, 226-230.	0.8	1
178	Public-Academic Partnerships: A Rapid Small-Grant Program for Policy-Relevant Research: Motivating Public-Academic Partnerships. Psychiatric Services, 2013, 64, 106-108.	2.0	1
179	Antipsychotic Medications for Schizophreniaâ€”Reply. JAMA - Journal of the American Medical Association, 2014, 312, 1469.	7.4	1
180	261. Metformin and 5-HT2C Agonist Lorcaserin for Weight Loss in Schizophrenia. Biological Psychiatry, 2018, 83, S105-S106.	1.3	1

#	ARTICLE	IF	CITATIONS
181	Psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. , 0, , 80-96.		0
182	Family outcomes. , 2010, , 133-155.		0
183	Statistical considerations. , 2010, , 22-38.		0
184	Cost-effectiveness and cost-benefit analysis. , 2010, , 57-79.		0
185	Metabolic side effects and risk of cardiovascular disease. , 0, , 173-188.		0
186	Genetic investigations in the CATIE sample. , 0, , 237-254.		0
187	Implications for research design and study implementation. , 0, , 281-287.		0
188	Conclusion and implications for practice and policy. , 0, , 288-306.		0
189	Human subjects considerations. , 2010, , 255-266.		0
190	Effectiveness and efficacy: staying on treatment and symptom reduction. , 2010, , 39-56.		0
191	Vocational outcomes. , 0, , 120-132.		0
192	Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia. Evidence-Based Mental Health, 2010, 13, 53-53.	4.5	0
193	No differences in efficacy of atypical and typical antipsychotics in early psychosis, but side effects differ. Evidence-Based Mental Health, 2011, 14, 25-25.	4.5	0
194	The need to determine the best options for people with schizophrenia that is unresponsive to treatment. Revista De Psiquiatr�a Y Salud Mental (English Edition), 2013, 6, 1-3.	0.3	0
195	Response to Rosenfeld. American Journal of Psychiatry, 2014, 171, 119-120.	7.2	0
196	Raising the standard of care for schizophrenia is an achievable goal. Australian and New Zealand Journal of Psychiatry, 2017, 51, 637-638.	2.3	0
197	Clozapine and Evidence-Based Psychopharmacology for Schizophrenia. JAMA Psychiatry, 2019, 76, 1007.	11.0	0
198	Examination of heterogeneity in treatment response to antipsychotic medications. Schizophrenia Research, 2019, 211, 100-102.	2.0	0